



Innate Biologics Enters Into Exclusive License Agreement with The Wistar Institute for Paired Protein Platform™

Philadelphia, PA — June 25, 2019 — Innate Biologics, LLC has entered into an exclusive license agreement with The Wistar Institute, an internationally recognized leader in biomedical research, to co-own patent rights related to a unique anti-inflammatory protein platform resulting from a 2018 research collaboration between Innate Biologics and Wistar.

Innate Biologics is pioneering technologies to treat and prevent inflammation, specifically targeting intracellular inflammatory signaling pathways. Innate Biologics therapeutic focus includes: inflammatory bowel disease, osteoarthritis, tumor micro-environment, and skin.

“Innate’s collaboration with Wistar has produced a diverse array of highly targeted, novel, and potent biologics with initial data supporting future therapeutic development,” said Peter Mondics, CEO and co-founder of Innate Biologics. “The scale of therapeutic applications, left largely vacant for sufferers of certain conditions like osteoarthritis and extrinsic skin issues, makes this undertaking a broad and material differentiator.”

Innate Biologics is in the pre-clinical stage of re-engineering bacterial effectors, both individually and paired, to treat and prevent diseases and pathologies stemming from broad, overactive innate inflammatory signaling. Effectors can be delivered orally, topically, intra-articularly, and through IV (intravenous).

###

About Innate Biologics

Innate Biologics is a privately held company targeting, treating, and preventing inflammation. Its first-of-its-kind, recombinant bacterial effector protein platform specifically targets intracellular inflammatory signaling pathways. Innate Biologics holds a growing Intellectual Property Catalogue with worldwide exclusive rights to a range of anti-inflammatory proteins including: full-length/optimized recombinant proteins, paired proteins and protein transduction domains. www.innatebiologics.com

This press release contains “forward-looking statements” concerning the development of Innate Biologics, LLC’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will be commercially successful. Forward-looking statements are subject to risk, assumptions, and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Innate Biologics, LLC undertakes no obligation to update any forward-looking statements for any reason.